Objectives of Study:
|
This topic through the prospectie cohort study "gout XiaoTong particles, uric acid particles" stage sequential therapy for acute phase of gout and intermittent period clinical signs and symptoms, TCM syndrome, blood uric acid, intervention of indicators, such as c-reactive protein and blood sedimentation, verify its anti-inflammatory and analgesic, blood uric acid to prevent the recurrence of disease, clinical efficacy and safety.To provide safe and effective prescriptions for TCM prevention and treatment of gout, improve the level of TCM prevention and treatment of gout.
|
Inclusion criteria
|
2.1 Inclusion criteria of acute stage: ① Meet the diagnostic criteria of acute gout arthritis in Western medicine;(2) in the acute stage, it meets the requirement of dampness and heat;(3) patients who were not treated with other drugs and methods at the time of onset;Those who volunteered to participate in the study and agreed to enter the clinical study, and those who signed the informed consent.2.2 Inclusion criteria for intermittent therapy: ① Patients with pain VAS ≤2 and blood uric acid ≥420μmol/L were included in intermittent therapy;② Patients with spleen deficiency and dampness resistance were assigned to the Chinese medicine group, while the rest were assigned to the Western medicine group.
|
Exclusion criteria:
|
① Those who do not meet the above inclusion criteria;② Secondary gout, arthritis caused by rheumatoid arthritis, suppurative arthritis, traumatic arthritis, silver arthritis, pseudogout, lupus erythematosus and other diseases.Chemotherapy, radiotherapy, chronic lead poisoning, acute obstructive nephropathy and other joint lesions;③ Acute joint pain was unbearable (grade 10);④ Long-term use of the following drugs, such as dihydrokeuride, furosemide, risuric acid, pyrazinamide, low-dose aspirin, and drugs containing the above ingredients, such as compound antihypertensive tablets, caused by gout;⑤ Allergic constitution, known to be allergic to the composition of the drug;⑥ Pregnant and lactating women;⑦ Mental patients;(8) Suspected or have a history of alcohol or drug abuse, or other diseases that, according to the judgment of the investigator, reduce the possibility of inclusion or complicate inclusion, such as frequent changes in the work environment and other conditions that are easy to cause loss of follow-up;⑨ Severe complications of heart, brain, liver, kidney or other serious primary diseases;⑩ blood ALT, AST, Cr more than 1 times the normal value;11 Patients who are participating in other clinical trials.
|